Anavex Life Sciences Corp (AVXL)

[Investor2014]

Worth reading this Oct 21, 2016 interview again for perspective.

https://www.sec.gov/Archives/edgar/data/1314052/000161577416007701/s104371_ex99-1.htm

An extract of stated facts in bold and my comments:

"SIGMACEPTOR Discovery Platform". Once one indication is hopefully proven...

"We will conduct the Phase 2/3 for Alzheimer’s." Did he know it will be P2/3 i.e. a P2 transitioning into a pivotal P3 on Oct 21, 2016 because of involvement with the Cures Act?

"Yes, we believe that sufficient financing in place and also because we are working with several foundations...". I believe Dr. M. means including LPC without saying so directly and of course how the company's fortunes and stock price may change with approval in a first indication.

Regarding Ariana: "patient stratification technology to potentially accelerate ANAVEX 2-73’s Phase 2/3 Alzheimer’s clinical development timelines". So we are waiting for it to go faster...seems a bit of a conundrum, but it may turn out to make sense...

About the Biogen MTA: "We are just providing the compound. After that, the evaluation will take place depending on what the findings are, and then discussions are expected to continue from that point on.". Hopefully deeper and more complicated discussions have been or is going on...and does Anavex owns the IP? "Yes, the company owns it."

"For larger markets like Alzheimer’s disease, partnerships for commercialization are very common.". Note "commercialization" i.e. post approval! "Our goal is always to create the highest possible value for shareholders. When you enter into such a collaboration or partnership for a larger indication, we will always try to aim for improving the outcome for the shareholders."

"We are consistently growing in a thoughtful manner and we are adding people selectively because we are still relatively small. So this will be at an incremental and carefully considered pace. We intend to have several clinical trials up and running next year. One will likely be an orphan indication. All those trials will be double-blind placebo-controlled studies.". The ODD trial being in Rett and one of the carefully selected members of the team being Dr. Fadiran.

As to what Missling is doing when not looking after his hair etc. "The chief challenge is really to keep in mind that drug development has inherent risks, and we would like to address those in order to reduce those risks to the extent possible. So we try to always do everything to the best of our knowledge and ability to minimize clinical trial risks in particular. That is the most important task for us and for me.". Froll should be happy with this recognition, which of course is only the preserve of very few on this iHub board.


Which of these statements from Missling have yet turned out to be false?